Preparing your space
Preparing your space
Conditions & Recovery · Oncology Brothers · August 25, 2026
We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody. We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wis
Originally published by Oncology Brothers. We curate and add context; they did the reporting.
Read the full story at Oncology Brothers ↗